Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET

Company Participants

Karina Calzadilla - Head, IR

Chad Robins - Co-Founder, CEO

Tycho Peterson - CFO

Harlan Robins - Chief Scientific Officer

Nitin Sood - Head of MRD

Sharon Benzeno - Head, Immune Medicine

Conference Call Participants

David Westenberg - Piper Sandler

Operator

Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Third Quarter Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Karina Calzadilla. Thank you. Please go ahead.

Karina Calzadilla

Thank you, Felicia, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies third quarter 2022 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial reports for the third quarter of '22. The press release is available at www.adaptivebiotech.com.

We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investors section in our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company.

These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and this presentation.

In addition, non-GAAP financial measures will be discussed during the call, and a reconciliation of non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robins, our CEO of Co-founder; and Tycho Peterson,0020our Chief Financial Officer.

In addition, Harlan Robins, Adaptive Chief Scientific Officer and Co-founder; Nitin Sood, Head of MRD business; and Head of Immune Medicine business will be available for Q&A.

With that, I'll turn the call over to Chad Robins. Chad?

Chad Robins

Thanks, Karina. Good afternoon, everybody, and thank you for joining us on our third quarter 2022 earnings call. As always, a big thank you to all our Adaptive employees for their dedication and for delivering another solid quarter.

As we approach year-end, we are well positioned to finish strong in both MRD and Immune Medicine. This quarter, as outlined on slide three, we achieved important milestones and results.